Synthetic Peroxisome Proliferator-Activated Receptor-γ Agonist, Rosiglitazone, Increases Plasma Levels of Adiponectin in Type 2 Diabetic Patients

Synthetic Peroxisome Proliferator-Activated Receptor-γ Agonist, Rosiglitazone, Increases Plasma Levels of Adiponectin in Type 2 Diabetic Patients Wei-Shiung Yang , MD, PHD 1 2 , Chi-Yuan Jeng , MD, PHD 3 , Ta-Jen Wu , MD, PHD 4 , Sachiyo Tanaka , MD, PHD 5 , Tohru Funahashi , MD, PHD 5 , Yuji Matsuzawa , MD, PHD 5 , Jao-Ping Wang , BS 1 , Chi-Ling Chen , PHD 6 , Tong-Yuan Tai , MD, PHD 1 and Lee-Ming Chuang , MD, PHD 1 2 1 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan 2 Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan 3 Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan 4 Department of Internal Medicine, National Cheng-Kung University Hospital, Tainan, Taiwan 5 Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Osaka, Japan 6 Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan Abstract OBJECTIVE —Adiponectin, a plasma protein exclusively synthesized and secreted by adipose tissue, has recently been shown to have anti-inflammatory, antiatherogenic properties in vitro and beneficial metabolic effects in animals. Lower plasma levels of adiponectin have been documented in human subjects with metabolic syndrome and coronary artery disease. We investigated whether the level of this putative protective adipocytokine could be increased by treatment with a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist in diabetic patients. RESEARCH DESIGN AND METHODS —Type 2 diabetic patients (30 in the treatment group and 34 in the placebo group) were recruited for a randomized double-blind placebo-controlled trial for 6 months with the PPAR-γ agonist rosiglitazone. Blood samples were collected and metabolic variables and adiponectin levels were determined in all patients before initiation of the study. RESULTS —In the rosiglitazone group, mean plasma adiponectin level was increased by more than twofold ( P < 0.0005), whereas no change was observed in the placebo group. Multivariate linear regression analysis showed that whether rosiglitazone was used was the single variable significantly related to the changes of plasma adiponectin. The amount of variance in changes of plasma adiponectin level explained by the treatment was ∼24% ( r 2 = 0.24) after adjusting for age, sex, and changes in fasting plasma glucose, HbA 1c , insulin resistance index, and BM